Literature DB >> 12728086

Immunogenicity of a three-component acellular pertussis vaccine administered at birth.

Cesare Belloni1, Annalisa De Silvestri, Carmine Tinelli, Maria A Avanzini, Massimo Marconi, Fabio Strano, Giorgio Rondini, Gaetano Chirico.   

Abstract

OBJECTIVE: To evaluate within the first 6 months of birth the immunogenicity of a 3-component acellular pertussis (aP) vaccine containing filamentous hemagglutinin (FHA), pertactine (PRN), and genetically detoxified pertussis toxin (PT) in infants who received a dose of vaccine at birth, in addition to the recommended schedule administered at 3, 5, and 11 months. Furthermore, we investigated the influence of maternal antibodies on aP vaccine response.
METHODS: We used enzyme-linked immunosorbent assay to evaluate immunoglobulin G antibody levels in 45 infants immunized at birth and at 3, 5, and 11 months (group 1) and in 46 infants immunized at the ages of 3, 5, and 11 months (group 2). All mothers were also tested at delivery.
RESULTS: At the age of 5 months the geometric mean titer of anti-PT, anti-FHA, and anti-PRN was significantly greater in group 1 (who had received 2 doses) than in group 2 (1 dose). At 6 months geometric mean titers were significantly higher in group 1 than in group 2 for anti-PRN and anti-FHA, whereas no significant differences were observed for anti-PT.
CONCLUSIONS: Immunization at birth may be important for an earlier prevention of the pertussis disease in infants under 6 months, especially in Italy, where the recommended ages for aP vaccine administration are 3, 5, and 11 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12728086     DOI: 10.1542/peds.111.5.1042

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  Infection of newborn piglets with Bordetella pertussis: a new model for pertussis.

Authors:  S Elahi; R Brownlie; J Korzeniowski; R Buchanan; B O'Connor; M S Peppler; S A Halperin; S F Lee; L A Babiuk; V Gerdts
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.

Authors:  Natasha B Halasa; Alice O'Shea; Jian R Shi; Bonnie J LaFleur; Kathryn M Edwards
Journal:  J Pediatr       Date:  2008-04-28       Impact factor: 4.406

3.  Genetically detoxified pertussis toxin induces superior antigen specific CD4 T cell responses compared to chemically detoxified pertussis toxin.

Authors:  Naveen Surendran; Michael Pichichero
Journal:  Hum Vaccin Immunother       Date:  2019-03-19       Impact factor: 3.452

Review 4.  Immunization During Pregnancy: Impact on the Infant.

Authors:  Kirsten P Perrett; Terry M Nolan
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

5.  Maternal and neonatal vaccination protects newborn baboons from pertussis infection.

Authors:  Jason M Warfel; James F Papin; Roman F Wolf; Lindsey I Zimmerman; Tod J Merkel
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

Review 6.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Pertussis re-emergence in the post-vaccination era.

Authors:  Elena Chiappini; Alessia Stival; Luisa Galli; Maurizio de Martino
Journal:  BMC Infect Dis       Date:  2013-03-26       Impact factor: 3.090

8.  Pertussis requiring intensive care.

Authors:  Julia Surridge; Elizabeth R Segedin; Cameron C Grant
Journal:  Arch Dis Child       Date:  2007-07-04       Impact factor: 3.791

Review 9.  B-cell responses to vaccination at the extremes of age.

Authors:  Claire-Anne Siegrist; Richard Aspinall
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

10.  Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.

Authors:  Nathalie Mielcarek; Anne-Sophie Debrie; Severine Mahieux; Camille Locht
Journal:  Clin Vaccine Immunol       Date:  2010-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.